Abstract
Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Current Molecular Pharmacology
Title: Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Volume: 3
Author(s): Hemant Varma
Affiliation:
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Abstract: Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Export Options
About this article
Cite this article as:
Varma Hemant, Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders, Current Molecular Pharmacology 2010; 3 (3) . https://dx.doi.org/10.2174/1874467211003030164
DOI https://dx.doi.org/10.2174/1874467211003030164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Doppler Haemodynamics of Cerebral Venous Return
Current Neurovascular Research Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinsons Disease
Mini-Reviews in Medicinal Chemistry Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases
Current Pharmaceutical Design Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Clinical Application of the Vestibular Stimulation Effect on Balance Disorders with Dementia
Current Alzheimer Research Use of Deoxyribozymes for Gene Knockdown
Medicinal Chemistry Reviews - Online (Discontinued) CHIP Knockdown Reduced Heat Shock Response and Protein Quality Control Capacity in Lens Epithelial Cells
Current Molecular Medicine S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Amyloid-Related Biomarkers for Alzheimers Disease
Current Medicinal Chemistry Protein Oxidative Folding in the Intermembrane Mitochondrial Space: More than Protein Trafficking
Current Protein & Peptide Science Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures
Current Pharmaceutical Design Editorial [Hot Topic: Advances in Alzheimer Therapy: Development of Innovative New Strategies (Guest Editors: Nigel H. Greig, Ezio Giacobini and Debomoy K. Lahiri)]
Current Alzheimer Research Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Computer-aided Drug Design Applied to Parkinson Targets
Current Neuropharmacology Subject Index To Volume 13
Current Medicinal Chemistry